O2L-001
Hemorrhagic Stroke (Intracerebral Hemorrhage)
Pre-clinicalActive
Key Facts
About Op2Lysis
Op2Lysis is a clinical-stage biotech targeting hemorrhagic stroke, a condition with high mortality and disability rates and no approved pharmacological therapy. The company's core innovation is the NANOp2Lysis® platform, which combines a novel engineered tissue plasminogen activator (OptPA) with a nanoparticle-based delivery system to enhance safety and efficacy in clot dissolution. With a strong founding team combining deep industry development and neurovascular research expertise, and backed by European grants like the EIC Accelerator, Op2Lysis is advancing O2L-001 through preclinical development toward clinical trials.
View full company profile